Chronic lymphocytic leukaemia+1
RecruitingStudy Comparing Nemtabrutinib, Ibrutinib, and Acalabrutinib for Patients with Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Study Comparing Nemtabrutinib, Ibrutinib, and Acalabrutinib for Patients with Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Disease:Chronic lymphocytic leukaemiaB-cell small lymphocytic lymphoma
- Substances:AcalabrutinibIbrutinib+1
Germany- Participants:18–64 years · 65+ years
- Substances:Acalabrutinib
- Sponsor:Merck Sharp & Dohme LLC










